Pharmaceuticals & Therapeutics

A Texas-based, private equity-backed firm just acquired a beloved local dermatology practice. It’s a story of national expansion, but what does it mean for care?

A new strategic partnership aims to overcome drug resistance in GI cancers by combining Lonza's advanced ADC platform with Antharis's targeted antibody expertise.

New Phase 3 data for Takeda's oveporexton shows it treats the root cause of narcolepsy, not just symptoms. A key FDA decision looms this year.

Big Pharma is pouring over $1 billion into AI to design complex drugs, trading lab guesswork for algorithms. It's a high-stakes play to fix a broken R&D model.

Restore Hyper Wellness is using a gamified challenge to keep clients engaged this summer. But is this a new frontier in personal resilience or just savvy marketing?

With air quality plummeting, a new wellness market is booming. We investigate the science and business behind lung health supplements for wildfire season.

With its 'Fan House' pop-up, SharkNinja and Amazon Ads are rewriting the retail playbook, proving that the best shopping cart is a lived experience.

Northann Corp. is back in the NYSE's good graces, but a closer look reveals a risky path. Can its innovative 3D printing tech overcome financial headwinds?

A new spirit called SHĀNG blends ancient Chinese baijiu with US whiskey tech. Is this the innovation that finally brings baijiu to the West?

A US food-tech innovator and a Bulgarian industrial giant are quadrupling animal-free egg protein production, signaling a tectonic shift in global supply chains.

A new precision drug, ART5803, is offering hope for a devastating brain disorder. Arialys Therapeutics is fast-tracking its development with key clinical trials.

With projections of $22.7M from four new supplements, Cosmos Health is betting big on the US. But can its 'science-driven' platform deliver in a crowded market?

Beyond a new PTSD campaign lies a strategic play. Cohen Veterans Network is leveraging philanthropy to build a global mental health system for veterans.

Minister Joly’s trip to China and Japan signals a strategic pivot, balancing guarded trade with Beijing against a deep tech and security alliance with Tokyo.

New data reveals elevated cortisol in over 75% of hard-to-treat diabetes patients, paving the way for a novel drug to tackle treatment resistance.

Fate Therapeutics' new board appointment signals a major shift. Can a commercial veteran turn groundbreaking iPSC science into accessible, off-the-shelf medicine?

A new study offers hope for MS by promoting nerve repair, but the real story is the validation of a versatile stem cell platform for a new era of medicine.

Facing a 'going concern' warning and collapsing revenue, Splash Beverage Group is ditching drinks for drugs. Its investment in Avicanna is a desperate, yet strategic, pivot.

Amidst a crisis in higher education, Bennington College's appointment of a psychoanalyst-artist-scholar as president is more than a hire—it's a bold strategy.

New data shows a national drop in overdose deaths, but a closer look reveals a fractured reality with regional surges and a dangerous new drug cocktail.